Shanghai, China, January 13, 2024 - Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into product license and supply agreement with Abbott, granting it exclusive or semi-exclusive licenses for the commercialization of four self-developed biosimilars and one innovative biologic in 69 emerging markets in Asia, Latin America and the Caribbean, as well as Middle East and Africa. This agreement builds on an existing collaboration between the two companies for the commercialization of oncology biosimilars.
Under this new agreement, the first molecules are anticipated to be launched in 2027, with some still subject to the completion of clinical development and registration. Abbott will secure the molecule registration in these regions and will launch the products by leveraging its broad presence and leadership position through its existing business. Henlius, a global biologics company focusing on oncology, autoimmune and ophthalmic diseases, will manufacture the medicines in its GMP-approved facility in Shanghai.
The expanded collaboration aims to enhance global access for patients to high-quality, affordable advanced biologics, reinforcing the commitment of both parties to deliver more advanced treatment options in emerging markets.
Ping Cao, Senior Vice President and Chief Business Development Officer of Henlius, said, “Henlius is delighted to reaffirm our collaboration with Abbott, a healthcare leader in emerging markets, realizing consistent growth with its trusted, high-quality established products, continuous technological advancements, and comprehensive local distribution networks. This expanded agreement is a testament of our common focus on expanding access to health, globally. We are confident that by pooling our joint efforts and expertise, we can deliver effective health solutions to emerging markets and improve standards of care for oncology.”